According to the study’s researchers; “Vascular dementia is the highly devastating neurodegenerative disorder after Alzheimer’s disease (AD) and mainly found in aged people but the effectual therapeutic target is still not there.” In addition; “Chronic cerebral hypoperfusion (CCH) has been broadly found in vascular dementia (VaD) patients.” CCH is thought to “link with neurodegenerative disorders and their subsequent cognitive deteriorate on.”
For the study, researchers examined “the role of a selective agonist of cannabinoid receptor type 2(CB2); 1-phenylisatin in CCH induced VaD [using rat models].”
In doing so, it was found that the CB2 agonist attenuated the CCH. “Hence”, researchers state, “it may be suggested that modulation of cannabinoid receptor may provide benefits in CCH as cognitive impairment and VaD.”
They conclude; “Therefore, selective agonists of CB2 receptors may be a potential research target for the alleviation of VaD.”
The full study, conducted at Amity University Uttar Prades in India, can be found by clicking here.
A separate study published last month by the Journal of Alzheimer’s Disease found that administration of THC and CBD – both cannabis compounds – is effective in treating dementia in its early stages, as well as its late stages.